Robot surgery grows fast – statistics leave quality questions open
Swiss hospitals counted 22,324 inpatient robot-assisted procedures in 2025. The new FSO data show growth and differences – but no automatic treatment advantage.
Robot-assisted surgery is growing rapidly in Swiss hospitals. The Federal Statistical Office (FSO) counts a total of 22,324 inpatient robot-assisted procedures for 2025. That is 25 percent more than in the previous year. Since 2021, the number has risen from 9,200 to more than 22,000 cases. The new statistics thus provide, for the first time, a clearer basis for a debate that has so far often been shaped by devices, brands and individual cases.
The most important limitation sits right beside it: figures on procedures are not a quality ranking. The FSO records inpatient cases and does not adjust its comparisons for treatment complexity. Anyone who sees shorter stays or higher costs cannot conclude that the surgical robot alone is the cause. The data show prevalence and differences – not automatic medical superiority.
Where robots are used most frequently
Robot-assisted procedures are not evenly distributed across all specialties. The largest case numbers in 2025 were total knee replacements with 4,475 procedures, hernia operations with 4,043, radical prostatectomies with 3,327 and nephrectomies with 1,304 cases. For prostate removals, 91 percent of recorded procedures were robot-assisted; for kidney removals the figure was 72 percent.
That explains why mere overall growth says little about the care provided. A procedure with high technical penetration cannot be equated with an orthopaedic operation or a hernia treatment. Patient selection may also differ. The statistics do not capture all the factors that influence the severity of a disease, pre-existing conditions or the decision for a particular method.
73 hospitals reported procedures
According to the FSO, 73 hospitals reported robot surgery in 2025. Among central care providers, 86 percent worked with such procedures; among basic care providers the figure was 39 percent, and among specialised surgical clinics 54 percent. The technology is therefore no longer limited to a few university hospitals. At the same time, it is not standard everywhere.
For patients, this can be relevant when they discuss where to receive treatment. What matters, however, is not only whether a hospital owns or uses a robot. More important are the team's experience, the suitability for the specific procedure, possible alternatives and the question of how complications are handled. A robot platform is a tool, not a diagnosis and not a promise of a particular outcome.
Costs and length of stay: a mixed picture
The FSO data show different patterns depending on the operation. For hernia operations, the reported case costs with the robot-assisted method were 11,672 francs, compared with 8,108 francs without a robot. For knee prostheses, by contrast, the costs were almost identical. Length of stay also differs: for prostatectomies the statistics show 4.2 days with a robot and 6.8 days without.
Such comparisons are interesting, but they need context. Shorter stays may be linked to the method, patient selection, hospital processes or the complexity of the case. Higher costs may reflect equipment, operating time, case mix or billing effects. The FSO therefore itself warns against drawing a causal conclusion from the data.
A distribution question remains visible
Insurance status is also striking. Semi-private and privately insured patients were more often operated on with robot assistance in several procedures. For radical prostatectomies their share was 32 percent, compared with 24 percent without a robot. Here too, no reason can be derived from the statistics alone. But the finding is a reason to demand transparency about referrals, indications and access.
The new FSO report thus moves the discussion to the right place. The decisive question is not «robot yes or no», but: for which patients, in which procedures, at what cost and with what verifiable benefit? The statistics do not answer everything. Precisely for that reason they are a valuable starting point for a factual quality debate in the Swiss healthcare system.
What a good discussion needs
For the next evaluation, more strongly risk-adjusted data would be particularly valuable: which cases were comparable, and how did complications, readmissions and long-term outcomes develop? Such questions cannot be answered with a single annual statistic. But they show what transparency is needed so that patients can make an informed choice.
